Results of first Phase III abiraterone acetate trial to be presented at ESMO

The “New” Prostate Cancer InfoLink has learned that the results of the Phase III clinical trial of abiraterone acetate + prednisone in patients who progressed after treatment with docetaxel-based chemotherapy will be presented on October 11 at the annual meeting of the European Society for Medical Oncology (ESMO) in Milan, Italy.

As previously reported, we know that the results of this trial are positive. This is confirmed by the title of the actual presentation: “Abiraterone acetate (AA) plus low dose prednisone (P) improves overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel-based chemotherapy (chemo): Results of COU-AA-301, a randomized double-blind placebo-controlled phase III study.” The actual presentation will be given by Dr. Johann de Bono — one of the principal investigators for this trial.

2 Responses

  1. That story is absolute BS, Professor Gerry Potter discovered abiraterone acetate in November 1990, that is 20 years ago, so it certainly is not a new discovery. Big Phama just didn’t do anything about it. Here is an email that I recieved from Prof. Potter last May

    “Dear John, I am so pleased to see you are progressing on the AbirateroneTrial, and as you can imagine it is very satisfying to see a drug that you have created coming to fruition. It has been a long struggle to proceed Abiraterone through all the preclinical and finally clinical trials, since it was 20 years ago that I invented abiraterone, as I remember it very clearly in November 1990. I knew this drug would be highly effective in treating prostate cancer, which is why I have been looking forward to this drug finally reaching phase 3.

    “I am pretty sure you are on the Abiraterone Cohort, since prednisone alone could not cause the PSA decrease that you are seeing. Let me reassure you though that the prednisone is there for a veryy good reason — it protects the patient from the mineralocorticoid imbalance that occurs when you achieve total CYP17 inhibition, I do hope you continue to respond and you cn be reassured by thefact that there are still people on Abiraterone after 4 years from the initial Phase 1 study.”

    Just imagine the number of prostate cancer sufferers that could have gained from the use of this drug earlier. It took 16 years from discovery to the first Phase I trial.

  2. I suppose what really gets my back up is the fact that Prof. Potter’s name is not even mentioned in the article and they are stating the following:

    “Peter Nelson, MD, a PCF-funded research at the University of Washington and the Fred Hutchinson Cancer in Seattle first discovered the mechanism of action of Abiraterone in 2007. Dr. Nelson’s findings sparked additional PCF funding in the form of two Challenge Awards and two Young Investigator Awards granted to researchers in his department.”

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: